動物用抗生物質市場：クラス別、動物タイプ別、エンドユーザー別、治療領域別 - 2025-2030年の世界予測

動物用抗生物質市場の2023年の市場規模は25億8,000万米ドルで、2024年には28億1,000万米ドル、CAGR 9.01%で成長し、2030年には47億3,000万米ドルに達すると予測されています。

動物用抗生物質は、動物の健康管理と治療の展望を変え続け、動物と人間の集団を守る上で重要な役割を果たしています。エグゼクティブサマリーでは、動物用抗生物質市場の現状と発展動向について詳細な分析を行い、新たな抗生物質耐性、規制圧力、進化する市場力学が生み出す課題と機会を取り上げています。この分析により、急速な変化を遂げつつある業界の複雑さを把握するための厳密な調査と的を絞った調査手法の重要性が強調されます。競争の激しい今日の世界環境において、医薬品開発者から動物医療従事者までの利害関係者は、詳細なデータ主導の考察によって戦略を調整する必要性を認識しています。本レポートの目的は、市場力学の包括的な概要を示すと同時に、複雑さと範囲の拡大を続けるこの分野における戦略的意思決定を支援する実用的な洞察を提供することです。

本レポートでは、まず動物用抗生物質の歴史的展望を土台に考察を始め、市場の期待を再定義する画期的な変化や技術革新の検証へと徐々に進んでいきます。有効性、安全性、環境への配慮という高い基準を遵守することの重要性は、規制の再編成、世界なサプライチェーンへの適応、抗生物質スチュワードシップの新たな必要性といった現代的な問題に対処するための十分な備えを業界のリーダーに保証するために、物語全体に織り込まれています。しっかりとしたイントロダクションで基礎固めをすることで、非常にダイナミックで、かつ現代の動物医療に不可欠な市場を深く掘り下げるための舞台を整えています。

動物用抗生物質の状況における変革的変化

近年、動物用抗生物質市場は、専門家が長年の課題にも新たな課題にも対処する方法を根本的に変える、変革的なシフトを経験しています。技術革新、規制の変更、そして市場力学の進化が融合し、より的を絞った効率的な抗生物質療法の開発が推進されています。

情勢における最も大きな変化のひとつは、精密獣医療への移行です。診断技術と遺伝子プロファイリングの進歩により、抗生物質治療を特定の細菌病原体や感染症に合わせる能力が高まっています。この精密なアプローチは治療成績を向上させるだけでなく、抗生物質の広範囲な使用や経験的な使用による耐性菌の出現を抑える上で極めて重要な役割を果たしています。

規制の枠組みの変化もまた、市場の変革に不可欠な役割を果たしています。畜産における抗生物質の使用に関する監視の強化は、厳格な安全性プロトコルと相まって、責任ある使用を強調する新しいガイドラインの開発につながりました。こうした規制の進展は、業界利害関係者に迅速な適応を促し、治療効果を維持しながらより高い基準に適合する新規製剤を生み出すための研究開発に投資しています。

さらに市場力学は、消費者意識の高まりとコンパニオンアニマルの健康重視の高まりの影響を受けています。ペットの飼い主が愛する動物に施す治療に対してより慎重になるにつれ、製薬会社は獣医の専門家を教育・訓練するプログラムを開始し、抗生物質の処方方法が最新の研究結果や責任ある投薬プロトコルに沿ったものとなるようにしています。

この変革の段階は、持続可能性、特に環境残留物の削減と生態系への影響の抑制を目的とした技術革新の開発における強力な努力によって補完されています。強化された診断技術、より包括的な規制、消費者の意識の高まりが相まって、精密性、安全性、持続可能な実践をますます優先させる市場が形成され、動物用抗生物質の使用が科学的根拠と倫理的管理の両面から確保されるようになっています。

クラス、動物種、エンドユーザー、治療分野別の主要なセグメンテーションの洞察

動物用抗生物質市場の詳細なセグメンテーションは、業界の多角的な理解を提供し、複雑なパターンと成長の機会を明らかにします。この市場は、抗生物質のクラス、治療を受ける動物のタイプ、エンドユーザーの設定、治療領域の概要など、複数の観点から分類されています。こうした多様なセグメンテーション基準に基づいて市場を調査することで、より的を絞った効果的な戦略決定を可能にする動向を特定することができます。

抗生物質の分類を考えると、アミノグリコシド系、アンフェニコール系、セファロスポリン系、フルオロキノロン系、マクロライド系、その他のキノロン系、ペニシリン系、ポリミキシン系、スルホンアミド系、テトラサイクリン系、トリメトプリム系など、さまざまな薬剤クラスが包括的に調査されていることがわかります。これらの薬剤クラスはさらに細分化され、アミノグリコシド系ではアミカシン、アプラマイシン、ゲンタマイシン、カナマイシン、ネオマイシンなどがあり、それぞれ耐性感染症の治療に独自の特徴を発揮します。同様に、アンフェニコール類はさらに細分化され、アジダムフェニコール、クロラムフェニコール、フローフェニコール、メチアマイシン、チアンフェニコールなどの化合物が含まれます。同様に、セファロスポリングループは、Cefalexin、Cefalonium、Cefazolin、Cefovecin、Ceftiofur、Ceftriaxoneの特定の市場ニッチを探索するために分解され、耐性菌に対処する際に、より集中的なアプローチを可能にします。フルオロキノロン系抗菌薬では、シプロフロキサシン、ダノフロキサシン、ジフロキサシン、エンロフロキサシン、ノルフロキサシン、オルビフロキサシン、マクロライド系抗菌薬では、アジスロマイシン、クラリスロマイシン、エリスロマイシン、ガミスロマイシン、スピラマイシン、チルミコシン、ツラスロマイシン、タイロシンが並行して分析されています。同様に、その他のキノロン系抗菌薬（Cinoxacin、Nalidixic Acid、Oxolinic Acid、Pipemidic Acid、Rosoxacinなど）のポートフォリオについても、市場の可能性をより深く理解するために精査しています。ペニシリンをアモキシシリン、アンピシリン、クロキサシリン、オキサシリン、ペニシリンG、ペニシリンVなどのサブカテゴリーに分類することで、製品の差別化を促進する重点的な洞察が可能になります。さらに、ポリミキシン類はコリスチン/ポリミキシンEとポリミキシンBに区分され、スルホンアミド類はスルファジアジン、スルファメラジン、スルファメチゾール、スルファメトキサゾール、スルファサラジンに区分されます。テトラサイクリン類は、クロルテトラサイクリン、ドキシサイクリン、オキシテトラサイクリン、テトラサイクリンなどのバリエーションで分析され、トリメトプリムクラスは、トリメトプリムプラススルファメタジン、トリメトプリム-スルファジアジン、トリメトプリム-スルファジミジン、トリメトプリム-スルファドキシン、トリメトプリム-スルファメトキサゾールなどの組み合わせを探るためにセグメント化されます。

複雑な薬剤分類とは別に、動物の種類別に市場を分析すると、治療対象動物の性格に基づく独自の動向が明らかになります。市場は伝統的に、コンパニオンアニマルと家畜という2つの重要なセグメントに分かれています。コンパニオンアニマルの領域では、治療は主に一般家庭のペット、特に犬猫に向けられ、治療アプローチはデリケートな生理学的環境における有効性と安全性のバランスをとる必要があります。一方、畜産分野では、牛、家禽、羊・山羊、豚など、より幅広い動物が対象となります。これらのグループは、変化する飼育方法、種特有の生理学、フードチェーンの安全性を確保することの重要性を反映した、オーダーメイドの治療戦略を必要とします。

さらに、エンドユーザー設定に基づくセグメンテーションは、市場エコシステムを形成するチャネル力学に関する洞察を提供します。特殊な動物生産施設の利用は、規模と効率の必要性によって推進されています。これは、個別ケアに重点を置く家庭のペットオーナーに見られる消費者主導の使用パターンによって補完されます。動物病院の役割は依然として非常に重要であり、これらの機関は先進的な研究と実際の現場での応用の接点として機能し、革新的な抗生物質療法のための肥沃な土壌を作り出しています。

最後に、市場内の治療領域を探ることで、動物用抗生物質に関連する応用範囲の広さが強調されます。評価では、皮膚感染症、消化器感染症、生殖器感染症、呼吸器感染症、軟部組織・創傷感染症、全身感染症、尿路感染症を含む一連の治療課題を取り上げています。これらの治療領域を異なる動物セグメント特有のニーズと関連付けることにより、利害関係者は経済的指標と臨床的指標の両方に基づいて介入策を調整することが可能となり、的を絞った研究、タイムリーな技術革新、カスタマイズされた治療プロトコールを通じて、各適用領域が最適な形で提供されることが保証されます。

要約すると、セグメンテーションは動物用抗生物質市場の複雑で重層的な性質を明らかにします。この詳細かつ構造化されたアプローチにより、マクロおよびミクロレベルの動向を深く理解し、的確な市場ターゲティングと各サブセグメント内の潜在的なビジネスチャンスを特定するための基盤を築くことができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 乳製品や肉製品の需要増加に伴う家畜頭数の増加
    • 動物における人獣共通感染症やその他の感染症の蔓延の増加
    • 世界中でペットとの交友関係が広がり、人間化が進む
  • 抑制要因
    • 獣医疾患抗原における抗生物質耐性に関する懸念の高まり
  • 機会
    • ドラッグデリバリーシステムの進歩により、動物用抗生物質の有効性と安全性が向上します。
    • 新しいメカニズムを持つ新しい抗生物質の開発による成長の可能性
  • 課題
    • さまざまな地域での動物用抗生物質の使用禁止および制限に関する問題
• 市場セグメンテーション分析
  • クラス：牛や魚の呼吸器疾患の治療にアンフェニコールの需要が各国で増加
  • 動物タイプ：安全な食品供給チェーンと農家の経済的安定を確保するための獣医用抗生物質家畜の使用
  • エンドユーザー：動物生産施設で動物用抗生物質を採用して、病気の発生を防ぎ、最適な成長率を確保します。
  • 治療領域：呼吸器感染症における動物用抗生物質の利用による発生防止と群れの健康維持,
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 動物用抗生物質市場：クラス別

• アミノグリコシド
  • アミカシン
  • アプラマイシン
  • ゲンタマイシン
  • カナマイシン
  • ネオマイシン
• アンフェニコール
  • アジダムフェニコール
  • クロラムフェニコール
  • フロルフェニコール
  • メチアマイシン
  • チアンフェニコール
• セファロスポリン
  • セファレキシン
  • セファロニウム
  • セファゾリン
  • セフォベシン
  • セフチオフル
  • セフトリアキソン
• フルオロキノロン
  • シプロフロキサシン
  • ダノフロキサシン
  • ジフロキサシン
  • エンロフロキサシン
  • ノルフロキサシン
  • オルビフロキサシン
• マクロライド
  • アジスロマイシン
  • クラリスロマイシン
  • エリスロマイシン
  • ガミスロマイシン
  • スピラマイシン
  • チルミコシン
  • ツラスロマイシン
  • タイロシン
• その他のキノロン
  • シノキサシン
  • ナリジクス酸
  • オキソリン酸
  • ピペミド酸
  • ロソキサシン
• ペニシリン
  • アモキシシリン
  • アンピシリン
  • クロキサシリン
  • オキサシリン
  • ペニシリンG
  • ペニシリンV
• ポリミキシン
  • コリスチン/ポリミキシンE
  • ポリミキシンB
• スルホンアミド
  • スルファジアジン
  • スルファメラジン
  • スルファメチゾール
  • スルファメトキサゾール
  • スルファサラジン
• テトラサイクリン
  • クロルテトラサイクリン
  • ドキシサイクリン
  • オキシテトラサイクリン
  • テトラサイクリン
• トリメトプリム
  • トリメトプリム＋スルファメタジン
  • トリメトプリム-スルファジアジン
  • トリメトプリム-スルファジミジン
  • トリメトプリム-スルファドキシン
  • トリメトプリム-スルファメトキサゾール（TMP-SMX）

第7章 動物用抗生物質市場：動物タイプ別

• コンパニオンアニマル
  • 猫
  • 犬
• 家畜
  • 牛
  • 家禽
  • 羊とヤギ
  • 豚

第8章 動物用抗生物質市場：エンドユーザー別

• 動物生産施設
• 家庭でペットを飼っている人
• 獣医クリニック

第9章 動物用抗生物質市場：治療領域別

• 皮膚感染症
• 胃腸感染症
• 生殖器感染症
• 呼吸器感染症
• 軟部組織および創傷感染症
• 全身感染症
• 尿路感染症

第10章 南北アメリカの動物用抗生物質市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の動物用抗生物質市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの動物用抗生物質市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Ashish Life Science Private Limited
• Bimeda Inc.
• Biogenesis Bago S.A.
• C.H. Boehringer Sohn AG & Co. KG
• Ceva Sante Animale
• Dechra Pharmaceuticals PLC
• Eco Animal Health Group PLC
• Elanco Animal Health Incorporated
• Intas Pharmaceuticals Ltd.
• Krka, d. d., Novo mesto
• Kyoritsuseiyaku Corporation
• LABORATORIO AVI-MEX
• LABORATORIOS CALIER, S.A.
• Merck KGaA
• Neogen Corporation
• Ourofino Group
• Sequent Scientific Ltd.
• Vetoquinol SA
• Virbac SA
• Zoetis Inc.

LIST OF FIGURES

• FIGURE 1. VETERINARY ANTIBIOTICS MARKET MULTI-CURRENCY
• FIGURE 2. VETERINARY ANTIBIOTICS MARKET MULTI-LANGUAGE
• FIGURE 3. VETERINARY ANTIBIOTICS MARKET RESEARCH PROCESS
• FIGURE 4. VETERINARY ANTIBIOTICS MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2030 (USD THOUSAND)
• FIGURE 6. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 12. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 14. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 16. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 18. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 20. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 24. VETERINARY ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. VETERINARY ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VETERINARY ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2030 (USD THOUSAND)
• TABLE 4. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 6. VETERINARY ANTIBIOTICS MARKET DYNAMICS
• TABLE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 11. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 12. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 13. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 14. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 15. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 16. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 17. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 18. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 19. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 20. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 21. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 22. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 23. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 24. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 25. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 26. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 27. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 28. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 29. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 30. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 31. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 32. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 33. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 34. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 35. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 36. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 37. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 38. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 39. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 40. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 41. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 42. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 43. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 44. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 45. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 46. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 47. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 48. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 49. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 50. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 51. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 52. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 53. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 54. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 55. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 56. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 57. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 58. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 59. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 60. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 61. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 62. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 63. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 64. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 65. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 66. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 67. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 68. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 69. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 70. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 71. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 72. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 73. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 74. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 75. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 76. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 77. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 78. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 79. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 80. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 81. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 82. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 83. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 84. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 85. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 86. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 87. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 88. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 89. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 90. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 91. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 92. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 93. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 94. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 95. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 96. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 97. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 98. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 99. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 100. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 101. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 102. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 103. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 104. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 105. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 106. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 107. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 108. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 109. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 110. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 111. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 112. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 113. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 114. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 115. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 116. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 117. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 118. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 119. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 120. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 121. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 122. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 123. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 124. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 125. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 126. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 127. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 128. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 129. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 130. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 131. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 132. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 133. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 134. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 135. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 136. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 137. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 138. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 139. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 140. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 141. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 142. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 143. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 144. ARGENTINA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 145. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 146. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 147. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 148. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 149. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 150. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 151. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 152. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 153. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 154. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 155. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 156. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 157. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 158. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 159. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 160. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 161. BRAZIL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 162. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 163. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 164. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 165. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 166. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 167. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 168. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 169. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 170. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 171. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 172. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 173. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 174. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 175. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 176. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 177. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 178. CANADA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 179. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 180. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 181. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 182. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 183. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 184. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 185. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 186. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 187. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 188. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 189. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 190. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 191. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 192. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 193. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 194. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 195. MEXICO VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 196. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 197. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 198. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 199. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 200. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 201. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 202. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 203. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 204. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 205. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 206. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 207. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 208. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 209. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 210. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 211. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 212. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 213. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
• TABLE 214. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 215. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 216. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 217. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 218. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 219. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 220. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 221. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 222. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 223. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 224. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 225. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 226. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 227. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 228. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 229. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 230. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 231. ASIA-PACIFIC VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 232. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 233. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 234. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 235. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 236. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 237. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 238. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 239. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 240. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 241. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 242. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 243. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 244. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 245. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 246. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 247. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 248. AUSTRALIA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 249. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 250. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 251. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 252. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 253. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 254. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 255. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 256. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 257. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 258. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 259. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 260. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 261. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 262. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 263. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 264. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 265. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 266. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 267. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 268. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 269. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 270. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 271. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 272. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 273. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 274. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 275. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 276. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 277. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 278. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 279. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 280. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 281. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 282. INDIA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 283. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 284. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 285. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 286. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 287. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 288. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 289. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 290. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 291. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 292. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 293. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 294. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 295. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 296. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 297. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 298. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 299. INDONESIA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 300. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 301. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 302. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 303. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 304. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 305. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 306. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 307. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 308. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 309. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 310. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 311. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)
• TABLE 312. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD THOUSAND)
• TABLE 313. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD THOUSAND)
• TABLE 314. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2030 (USD THOUSAND)
• TABLE 315. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2030 (USD THOUSAND)
• TABLE 316. JAPAN VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD THOUSAND)
• TABLE 317. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2030 (USD THOUSAND)
• TABLE 318. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2030 (USD THOUSAND)
• TABLE 319. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2030 (USD THOUSAND)
• TABLE 320. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2030 (USD THOUSAND)
• TABLE 321. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 322. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2030 (USD THOUSAND)
• TABLE 323. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2030 (USD THOUSAND)
• TABLE 324. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2030 (USD THOUSAND)
• TABLE 325. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2030 (USD THOUSAND)
• TABLE 326. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2030 (USD THOUSAND)
• TABLE 327. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2030 (USD THOUSAND)
• TABLE 328. MALAYSIA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2030 (USD THOUSAND)

The Veterinary Antibiotics Market was valued at USD 2.58 billion in 2023 and is projected to grow to USD 2.81 billion in 2024, with a CAGR of 9.01%, reaching USD 4.73 billion by 2030.

Veterinary antibiotics continue to reshape the landscape of animal health management and treatment, playing a critical role in safeguarding both animal and human populations. The executive summary presents an in-depth analysis of the current state and evolving trends in the veterinary antibiotics market, addressing challenges and opportunities created by emerging antibiotic resistance, regulatory pressures, and evolving market dynamics. This analysis underscores the importance of rigorous research and targeted research methodologies to capture the intricacies of an industry undergoing rapid transformation. In today's highly competitive global environment, stakeholders-from pharmaceutical developers to veterinary practitioners-are recognizing the necessity of aligning their strategies with detailed, data-driven insights. The purpose of this report is to present a comprehensive overview of the market dynamics while providing actionable insights that support strategic decision-making within a field that continues to expand in both complexity and scope.

Our discussion begins with a reflection on the historical perspective of veterinary antibiotics as a foundation, gradually progressing to an examination of groundbreaking changes and technological innovations that are redefining market expectations. The importance of adhering to high standards of efficacy, safety, and environmental considerations is interwoven throughout the narrative, ensuring that industry leaders are well prepared to address contemporary issues such as regulatory realignment, global supply chain adaptation, and the emerging need for antibiotic stewardship. By laying the groundwork with a robust introduction, we set the stage for a deep dive into a market that is both highly dynamic and essential to modern animal health care.

Transformative Shifts in the Veterinary Antibiotics Landscape

In recent years, the veterinary antibiotics market has experienced transformative shifts that are fundamentally altering the way professionals address both longstanding and emergent challenges. Technological innovations, regulatory changes, and evolving market dynamics have converged to drive the development of more targeted and efficient antibiotic therapies.

One of the most significant shifts in the landscape is the transition toward precision veterinary medicine. With advances in diagnostic technologies and genetic profiling, there is a growing ability to tailor antibiotic treatments to specific bacterial pathogens and infections. This precision approach not only improves treatment outcomes but also plays a pivotal role in reducing the emergence of resistance from widespread or empirical antibiotic use.

Changing regulatory frameworks have also played an essential role in catalyzing market transformations. Increased scrutiny regarding the use of antibiotics in animal agriculture, combined with stringent safety protocols, has led to the development of new guidelines that emphasize responsible usage. These evolving regulations are prompting industry stakeholders to adapt quickly, investing in research and development to create novel formulations that comply with higher standards while maintaining therapeutic efficacy.

Additionally, market dynamics are being influenced by heightened consumer awareness and an increased emphasis on the health of companion animals. As pet owners become more conscientious about the treatments administered to their beloved animals, pharmaceutical companies have initiated programs to educate and train veterinary professionals, ensuring that antibiotic prescription practices are aligned with contemporary research findings and responsible medication protocols.

This stage of transformation is complemented by robust efforts in sustainability, particularly the development of innovations aimed at reducing environmental residues and limiting ecological impacts. The combined effects of enhanced diagnostic techniques, more comprehensive regulations, and growing consumer awareness are driving a market that increasingly prioritizes precision, safety, and sustainable practices, ensuring that the use of veterinary antibiotics is both scientifically grounded and ethically managed.

Key Segmentation Insights into Class, Animal Type, End-User, and Therapeutic Areas

A detailed segmentation of the veterinary antibiotics market provides a multi-dimensional understanding of the industry, unveiling intricate patterns and opportunities for growth. The market has been categorized from multiple perspectives, such as the class of antibiotics, the type of animal receiving treatment, the end-user setting, and the therapeutic areas that outline the range of infections treated. By examining the market based on these diverse segmentation criteria, one can identify trends that allow for more targeted and effective strategic decisions.

When considering the classification of antibiotics, it is evident that a variety of drug classes such as Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim have been studied comprehensively. These classes are further subdivided for granular analysis, with Aminoglycosides including drugs such as Amikacin, Apramycin, Gentamicin, Kanamycin, and Neomycin, each offering unique characteristics for treating resistant infections. Similarly, Amphenicols are further delineated to include compounds like Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, and Thiamphenicol. In the same manner, the Cephalosporins group is broken down to explore the specific market niches of Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, and Ceftriaxone, enabling a more focused approach when addressing bacterial resistance. With Fluoroquinolones, research encompasses Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, and Orbifloxacin, while Macrolides such as Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, and Tylosin are analyzed in parallel. Similarly, the portfolio of Other Quinolones-which includes Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, and Rosoxacin-is scrutinized to better understand its market potential. The division of Penicillins into sub-categories featuring Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, and Penicillin V enables focused insights that drive product differentiation. Moreover, the Polymixins segment is further demarcated into Colistin/Polymyxin E and Polymyxin B, while the Sulfonamides class is detailed by studying Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, and Sulfasalazine. The Tetracyclines are analyzed across variations such as Chlortetracycline, Doxycycline, Oxytetracycline, and Tetracycline, and the Trimethoprim class is segmented to explore combinations like Trimethoprim Plus Sulfamethazine, Trimethoprim-Sulfadiazine, Trimethoprim-Sulfadimidine, Trimethoprim-Sulfadoxine, and Trimethoprim-Sulfamethoxazole.

Apart from the intricate drug classifications, analyzing the market by animal type reveals unique trends based on the character of the treated animal. The market traditionally divides into two essential segments-Companion Animals and Livestock. Within the sphere of companion animals, treatments are primarily directed toward common household pets, particularly cats and dogs, where therapeutic approaches need to balance efficacy and safety in delicate physiological environments. Conversely, the livestock segment includes a broader array of animals such as cattle, poultry, sheep and goats, and swine. These groups require tailored treatment strategies reflective of changing husbandry practices, species-specific physiology, and the critical importance of ensuring the food chain's safety.

Furthermore, the segmentation based on end-user settings provides insights into the channel dynamics that shape the market ecosystem. The utilization in specialized animal production facilities is driven by the need for scale and efficiency. This is complemented by the consumer-driven usage patterns observed among household pet owners, where a focus on individualized care is paramount. The role of veterinary clinics remains invaluable, as these institutions act as the interface between advanced research and practical, on-ground application, creating a fertile ground for innovative antibiotic therapies.

Finally, the exploration of therapeutic areas within the market underscores the wide range of applications associated with veterinary antibiotics. Assessment covers a series of therapeutic challenges including dermatological infections, gastrointestinal infections, infections of the reproductive system, respiratory infections, soft tissue and wound infections, systemic infections, and urinary tract infections. By correlating these therapeutic areas with the specific needs of different animal segments, stakeholders are enabled to tailor interventions based on both economic and clinical metrics, ensuring that each application area is optimally served through targeted research, timely innovation, and customized treatment protocols.

In summary, segmentation reveals the complex and layered nature of the veterinary antibiotics market. It is this detailed and structured approach that allows for an in-depth understanding of both macro and micro-level trends, laying the foundation for precise market targeting and the identification of latent opportunities within every sub-segment.

Based on Class, market is studied across Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim. The Aminoglycosides is further studied across Amikacin, Apramycin, Gentamicin, Kanamycin, and Neomycin. The Amphenicols is further studied across Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, and Thiamphenicol. The Cephalosporins is further studied across Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, and Ceftriaxone. The Fluoroquinolones is further studied across Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, and Orbifloxacin. The Macrolides is further studied across Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, and Tylosin. The Other Quinolones is further studied across Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, and Rosoxacin. The Penicillins is further studied across Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, and Penicillin V. The Polymixins is further studied across Colistin/Polymyxin E and Polymyxin B. The Sulfonamides is further studied across Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, and Sulfasalazine. The Tetracyclines is further studied across Chlortetracycline, Doxycycline, Oxytetracycline, and Tetracycline. The Trimethoprim is further studied across Trimethoprim Plus Sulfamethazine, Trimethoprim-Sulfadiazine, Trimethoprim-Sulfadimidine, Trimethoprim-Sulfadoxine, and Trimethoprim-Sulfamethoxazole (TMP-SMX).

Based on Animal Type, market is studied across Companion Animals and Livestock. The Companion Animals is further studied across Cats and Dogs. The Livestock is further studied across Cattle, Poultry, Sheep & Goats, and Swine.

Based on End-User, market is studied across Animal Production Facilities, Household Pet Owners, and Veterinary Clinics.

Based on Therapeutic Areas, market is studied across Dermatological Infections, Gastrointestinal Infections, Reproductive System Infections, Respiratory Infections, Soft Tissue & Wound Infections, Systemic Infections, and Urinary Tract Infections.

Analyzing Key Regional Insights Across Global Markets

A meticulous examination of the geographic landscape illustrates significant regional disparities and growth drivers that influence the global veterinary antibiotics market. The distinct markets in the Americas, Europe, Middle East & Africa, and Asia-Pacific each present unique characteristics that not only reflect local economic and regulatory conditions but also denote significant potential for strategic expansion and investment.

In the Americas, market dynamics have been marked by a swift adaptation to evolving regulatory frameworks and heightened consumer awareness regarding animal welfare and public health. These factors have spurred market growth, supported by high adoption rates of precision treatments and modern therapeutic approaches in both companion animal and livestock sectors. Regional economic stability and an increasing focus on innovation have bolstered research and development initiatives, enabling breakthroughs in treatment efficacy and safety.

Europe, along with the Middle East & Africa, exhibits a complex interplay of regulatory restrictions and collaborative research. European markets in particular benefit from a highly regulated environment, necessitating strict compliance and comprehensive stewardship measures that influence product development pipelines. The focus on sustainability and environmental protection further encourages the development of antibiotics with reduced ecological footprints. In the Middle East & Africa, market growth is driven by a rising demand for improved animal health protocols as emerging economies invest in modernizing their agricultural practices and veterinary care systems. These regions are witnessing increasing governmental support for enhanced veterinary services, indirectly fostering expansions in the availability and diversity of antibiotic treatments.

The Asia-Pacific market is distinguished by dynamic economic growth and rapid urbanization that are reshaping livestock practices and pet ownership trends. Increased disposable incomes, accelerated technological adoption, and expanding consumer bases in emerging countries contribute to the heightened demand for state-of-the-art veterinary care. The region's market is characterized by high-volume production of veterinary antibiotics tailored to meet diverse requirements across both extensive livestock operations and the evolving pet care segment. Additionally, the Asia-Pacific markets frequently benefit from proactive public and private partnerships which drive investments into research, manufacturing efficiency, and the integration of global best practices in veterinary medicine.

Altogether, the divergence and distinctiveness of regional markets underscore the importance of localized strategies that consider cultural, economic, and regulatory factors. A deep understanding of these geographical nuances enables stakeholders to harness growth opportunities tailored to specific markets while maintaining a cohesive global strategy that leverages innovation and sustainability.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Profile of Leading Companies Driving Growth and Innovation

The competitive landscape of the veterinary antibiotics market is spearheaded by a dynamic cohort of companies, each contributing to the sector's innovation and market expansion. In this environment, organizations such as Ashish Life Science Private Limited, Bimeda Inc., and Biogenesis Bago S.A. have differentiated themselves through rigorous research and a steadfast commitment to high-quality product portfolios. These companies have become known for integrating cutting-edge technologies into their production processes, resulting in therapies that are both effective and safe.

Other industry leaders, including C.H. Boehringer Sohn AG & Co. KG and Ceva Sante Animale, have built strong reputations by leveraging deep expertise in both human and veterinary pharmaceuticals. They maintain strategic collaborations with research institutions, enabling them to keep pace with the rapidly evolving scientific environment and ensure that their product offerings are based on the latest clinical evidence. Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, and Elanco Animal Health Incorporated also play critical roles, driving market growth through focused investment in research and an unyielding commitment to meeting modern regulatory standards.

Intas Pharmaceuticals Ltd., along with established entities such as Krka, d. d., Novo mesto, continues to expand their presence by capitalizing on innovation and diversification of product pipelines. Kyoritsuseiyaku Corporation and LABORATORIO AVI-MEX represent robust contributors in this competitive landscape, underscoring the ever-more global reach of the industry. LABORATORIOS CALIER, S.A., Merck KGaA, Neogen Corporation, and Ourofino Group have all demonstrated a capacity to adapt to shifting market demands through agile business strategies and the consistent delivery of high-performance therapies. Moreover, companies like Sequent Scientific Ltd., Vetoquinol SA, Virbac SA, and Zoetis Inc. have reinforced their market positions through strategic acquisitions, expansive research initiatives, and a deep-rooted dedication to advancing animal health. Their comprehensive and specialized portfolios enable them to meet a diverse range of veterinary needs while staying competitive amid evolving industry trends.

The robust profile of these key companies reflects an unwavering commitment to innovation, quality, and customer-centric solutions. By continuously investing in research and embracing strategic mergers and alliances, these leading players are not only bolstering their market shares but also contributing to significant advancements that are shaping the future of veterinary medicine. Their efforts are driving improvements in both therapeutic efficacy and sustainable practices, ensuring that animal health remains at the forefront of the global veterinary antibiotics market.

The report delves into recent significant developments in the Veterinary Antibiotics Market, highlighting leading vendors and their innovative profiles. These include Ashish Life Science Private Limited, Bimeda Inc., Biogenesis Bago S.A., C.H. Boehringer Sohn AG & Co. KG, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Eco Animal Health Group PLC, Elanco Animal Health Incorporated, Intas Pharmaceuticals Ltd., Krka, d. d., Novo mesto, Kyoritsuseiyaku Corporation, LABORATORIO AVI-MEX, LABORATORIOS CALIER, S.A., Merck KGaA, Neogen Corporation, Ourofino Group, Sequent Scientific Ltd., Vetoquinol SA, Virbac SA, and Zoetis Inc.. Actionable Recommendations to Enhance Market Positioning and Growth

For industry leaders seeking to capitalize on emerging trends and reinforce their market positioning, several actionable recommendations can be drawn from the current analysis. Foremost, a sustained commitment to research and development is essential. Leaders should invest in innovative diagnostic technologies and precision medicine approaches, thereby enabling the creation of targeted antibiotic therapies that not only improve treatment outcomes but also address concerns related to antimicrobial resistance.

It is equally important for decision-makers to prioritize regulatory compliance and proactive engagement with evolving legislation. By maintaining close collaboration with regulatory bodies and ensuring that product development strategies are aligned with globally recognized standards, companies can safeguard their market presence and avert potential setbacks related to non-compliance.

In addition, market expansion strategies should be driven by a granular understanding of regional dynamics. Firms need to tailor their approaches based on detailed insights into the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. This localized strategy will enable companies to optimize resource allocation, adapt product formulations to meet specific regional requirements, and leverage partnerships with local stakeholders to enhance distribution networks.

Another key consideration is the embrace of digital transformation. Investing in advanced analytics and artificial intelligence can provide real-time insights into market trends, customer behavior, and competitive activity. A data-driven approach not only enhances decision-making processes but also ensures agile responses to rapid market changes. Furthermore, companies would benefit by expanding collaborations with research institutions and industry experts to foster innovation and develop sustainable practices that lessen environmental impact.

Finally, organizations must adopt a customer-centric model that emphasizes tailored solutions in both companion animal and livestock segments. This approach requires continuous engagement with veterinary practitioners, training initiatives for end users, and comprehensive support systems that ensure the successful implementation of new therapies. By integrating these strategies, industry leaders can solidify their competitive edge, drive sustainable growth, and contribute positively to the broader narrative of veterinary healthcare innovation.

Concluding Reflections on the Veterinary Antibiotics Market

The comprehensive analysis underscores the intricate dynamics underpinning the current and future state of the veterinary antibiotics market. This exploration has traversed a spectrum of key dimensions, from transformative innovations and nuanced segmentation insights to region-specific trends and the strategic moves of industry titans. At every level, the narrative reveals a market that is not only vast in its complexity but also rich with opportunities for investment, growth, and sustainable development.

A critical takeaway from this review is the importance of balancing rapid technological advancements with steadfast commitments to safety, regulatory compliance, and environmental considerations. The sector's evolution is being driven by a robust demand for precision in animal health interventions, alongside an urgent need to mitigate issues related to antimicrobial resistance. As veterinary professionals and industry stakeholders capitalize on these trends, it becomes evident that success will depend on an adaptive approach that embraces both local nuances and global best practices.

The integrated insights presented herein serve not only as a reflection of the market condition but also as a roadmap for future strategic directions. The interplay between scientific innovation, regulatory evolution, and market expansion creates a fertile ground for further breakthroughs, ultimately driving enhanced health outcomes for animals across various segments. Reflecting on these factors, it is clear that the veterinary antibiotics market is poised to offer substantial rewards for those who navigate its challenges with foresight and strategic agility.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing livestock population with increasing demand for dairy and meat products
    • 5.1.1.2. Rising prevalence of zoonotic diseases and other infections in animals
    • 5.1.1.3. Increasing companionship and humanization of pets across the globe
  • 5.1.2. Restraints
    • 5.1.2.1. Growing concerns about antibiotic resistance in veterinary disease antigens
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in drug delivery systems that enhance the efficacy and safety of veterinary antibiotics
    • 5.1.3.2. Growing potential with the development of new antibiotics with novel mechanisms
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to the ban and restricted use of veterinary antibiotics in different regions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Class: Rising demand for amphenicols in various countries for treating respiratory diseases in cattle and fish
  • 5.2.2. Animal Type: Usage of veterinary-antibiotics livestocks to ensure safe food supply chains and economic stability for farmers
  • 5.2.3. End-User: Adoption of veterinary antibiotics in animal production facilities to prevent disease outbreaks and ensure optimal growth rates.
  • 5.2.4. Therapeutic Areas: Utilization of veterinary antibiotics in respiratory infection to prevent outbreaks and maintain herd health,
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Veterinary Antibiotics Market, by Class

• 6.1. Introduction
• 6.2. Aminoglycosides
  • 6.2.1. Amikacin
  • 6.2.2. Apramycin
  • 6.2.3. Gentamicin
  • 6.2.4. Kanamycin
  • 6.2.5. Neomycin
• 6.3. Amphenicols
  • 6.3.1. Azidamfenicol
  • 6.3.2. Chloramphenicol
  • 6.3.3. Florfenicol
  • 6.3.4. Metiamycin
  • 6.3.5. Thiamphenicol
• 6.4. Cephalosporins
  • 6.4.1. Cefalexin
  • 6.4.2. Cefalonium
  • 6.4.3. Cefazolin
  • 6.4.4. Cefovecin
  • 6.4.5. Ceftiofur
  • 6.4.6. Ceftriaxone
• 6.5. Fluoroquinolones
  • 6.5.1. Ciprofloxacin
  • 6.5.2. Danofloxacin
  • 6.5.3. Difloxacin
  • 6.5.4. Enrofloxacin
  • 6.5.5. Norfloxacin
  • 6.5.6. Orbifloxacin
• 6.6. Macrolides
  • 6.6.1. Azithromycin
  • 6.6.2. Clarithromycin
  • 6.6.3. Erythromycin
  • 6.6.4. Gamithromycin
  • 6.6.5. Spiramycin
  • 6.6.6. Tilmicosin
  • 6.6.7. Tulathromycin
  • 6.6.8. Tylosin
• 6.7. Other Quinolones
  • 6.7.1. Cinoxacin
  • 6.7.2. Nalidixic Acid
  • 6.7.3. Oxolinic Acid
  • 6.7.4. Pipemidic Acid
  • 6.7.5. Rosoxacin
• 6.8. Penicillins
  • 6.8.1. Amoxicillin
  • 6.8.2. Ampicillin
  • 6.8.3. Cloxacillin
  • 6.8.4. Oxacillin
  • 6.8.5. Penicillin G
  • 6.8.6. Penicillin V
• 6.9. Polymixins
  • 6.9.1. Colistin/Polymyxin E
  • 6.9.2. Polymyxin B
• 6.10. Sulfonamides
  • 6.10.1. Sulfadiazine
  • 6.10.2. Sulfamerazine
  • 6.10.3. Sulfamethizole
  • 6.10.4. Sulfamethoxazole
  • 6.10.5. Sulfasalazine
• 6.11. Tetracyclines
  • 6.11.1. Chlortetracycline
  • 6.11.2. Doxycycline
  • 6.11.3. Oxytetracycline
  • 6.11.4. Tetracycline
• 6.12. Trimethoprim
  • 6.12.1. Trimethoprim Plus Sulfamethazine
  • 6.12.2. Trimethoprim-Sulfadiazine
  • 6.12.3. Trimethoprim-Sulfadimidine
  • 6.12.4. Trimethoprim-Sulfadoxine
  • 6.12.5. Trimethoprim-Sulfamethoxazole (TMP-SMX)

7. Veterinary Antibiotics Market, by Animal Type

• 7.1. Introduction
• 7.2. Companion Animals
  • 7.2.1. Cats
  • 7.2.2. Dogs
• 7.3. Livestock
  • 7.3.1. Cattle
  • 7.3.2. Poultry
  • 7.3.3. Sheep & Goats
  • 7.3.4. Swine

8. Veterinary Antibiotics Market, by End-User

• 8.1. Introduction
• 8.2. Animal Production Facilities
• 8.3. Household Pet Owners
• 8.4. Veterinary Clinics

9. Veterinary Antibiotics Market, by Therapeutic Areas

• 9.1. Introduction
• 9.2. Dermatological Infections
• 9.3. Gastrointestinal Infections
• 9.4. Reproductive System Infections
• 9.5. Respiratory Infections
• 9.6. Soft Tissue & Wound Infections
• 9.7. Systemic Infections
• 9.8. Urinary Tract Infections

10. Americas Veterinary Antibiotics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Veterinary Antibiotics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Veterinary Antibiotics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Innovative Vetlen pouch enhances antibiotic delivery for veterinary care
  • 13.3.2. Innovative antibacterial agents target antibiotic-resistant infections
  • 13.3.3. FDA establishes veterinary innovation centers to advance animal health
  • 13.3.4. Purdue and Akston Biosciences partner for innovative canine cancer treatment development
  • 13.3.5. Dechra Pharmaceuticals to acquire invetx for enhanced veterinary biotherapeutics portfolio
  • 13.3.6. FDA approves pradalex for targeted Use in cattle and swine respiratory treatment
  • 13.3.7. Blacksmith Medicines and Zoetis collaborate to tackle antibiotic resistance in animal health
• 13.4. Strategy Analysis & Recommendation
  • 13.4.1. Intas Pharmaceuticals Ltd.
  • 13.4.2. Merck KGaA
  • 13.4.3. Elanco Animal Health Incorporated
  • 13.4.4. Zoetis Inc.

Companies Mentioned

• 1. Ashish Life Science Private Limited
• 2. Bimeda Inc.
• 3. Biogenesis Bago S.A.
• 4. C.H. Boehringer Sohn AG & Co. KG
• 5. Ceva Sante Animale
• 6. Dechra Pharmaceuticals PLC
• 7. Eco Animal Health Group PLC
• 8. Elanco Animal Health Incorporated
• 9. Intas Pharmaceuticals Ltd.
• 10. Krka, d. d., Novo mesto
• 11. Kyoritsuseiyaku Corporation
• 12. LABORATORIO AVI-MEX
• 13. LABORATORIOS CALIER, S.A.
• 14. Merck KGaA
• 15. Neogen Corporation
• 16. Ourofino Group
• 17. Sequent Scientific Ltd.
• 18. Vetoquinol SA
• 19. Virbac SA
• 20. Zoetis Inc.